Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  MyoKardia, Inc.    MYOK

MYOKARDIA, INC.

(MYOK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 33,6 M - -
Net income 2018 -67,7 M - -
Net cash position 2018 315 M - -
P/E ratio 2018 -27,7x
Yield 2018 -
Sales 2019 - - -
Net income 2019 -276 M - -
Net cash position 2019 416 M - -
P/E ratio 2019 -11,8x
Yield 2019 -
Capitalization 11 993 M 11 993 M -
EV / Sales 2018 49,3x
EV / Sales 2019 -
Nbr of Employees 318
Free-Float 94,3%
More Financials
Company
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an... 
More about the company
Notations Surperformance© of MyoKardia, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about MYOKARDIA, INC.
11/18BRISTOL MYERS SQUIBB : Completes Acquisition of MyoKardia, Strengthening Company..
AQ
11/17MYOKARDIA, INC. : Termination of a Material Definitive Agreement, Completion of ..
AQ
11/16MYOKARDIA : Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mav..
AQ
11/16MYOKARDIA : Presents Mavacamten Clinical and Non-Clinical Data at the American H..
AQ
11/15MYOKARDIA : Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mav..
AQ
11/15MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Ma..
GL
11/13MYOKARDIA : Presents Mavacamten Clinical and Non-Clinical Data at the American H..
AQ
11/13MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American ..
GL
11/11MYOKARDIA : Collaborates with the American College of Cardiology and PINNACLE/Ve..
AQ
11/11MyoKardia Collaborates with the American College of Cardiology and PINNACLE/V..
GL
11/05MYOKARDIA : 3Q Earnings Snapshot
AQ
11/05MYOKARDIA : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/05MYOKARDIA, INC. : Results of Operations and Financial Condition, Financial State..
AQ
11/05MYOKARDIA : Reports Third Quarter 2020 Financial Results
AQ
11/05MyoKardia Reports Third Quarter 2020 Financial Results
GL
More news
News in other languages on MYOKARDIA, INC.
11/16Des idées d'ETF pour miser sur le retour en grâce des valeurs moyennes
11/05MYOKARDIA, INC. : Veröffentlichung des Quartalsergebnisses
11/05MYOKARDIA, INC. : publication des résultats trimestriels
10/05Aktien New York Schluss: Trump-Erholung sorgt für starken Wochenauftakt
10/05Aktien New York: Gewinne - Nachlassende Unsicherheit dank Trump-Genesungsproz..
More news
Analyst Recommendations on MYOKARDIA, INC.
More recommendations
Chart MYOKARDIA, INC.
Duration : Period :
MyoKardia, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYOKARDIA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 224,91 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Anastasios E. Gianakakos President, Chief Executive Officer & Director
Taylor C. Harris Chief Financial Officer
Robert Scott McDowell Chief Scientific Officer
Jay Edelberg Senior Vice President-Clinical Development
Mark L. Perry Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MYOKARDIA, INC.208.58%11 993
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.55.32%37 691
BIONTECH SE209.80%25 273